XKRX
003850
Market cap541mUSD
Oct 08, Last price
8,610.00KRW
1D
-1.82%
1Q
1.65%
Jan 2017
-6.55%
Name
Boryung Corp
Chart & performance
P/E
11.31
P/S
0.71
EPS
761.16
Div yield, %
1.86%
Shrs. gr., 5y
7.16%
Rev. gr., 5y
12.61%
Revenues
1.02t
+0.03%
Net income
64.30b
-7.65%
CFO
133.18b
+65.32%
Dividend
Dec 29, 2025160 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, South Korea.
Key people
Vice President
Managing Director · since 2023
Seong Won Choi
Managing Director
Wung Je Jung
Managing Director
Bong Seok Kim
Managing Director
Yeong Seok Kim
Managing Director · since 2023
Gyeong Suk Park
Managing Director · since 2023
Eun Ah Baek
Assistant Managing Director
Seong Nam Cheon
Assistant Managing Director
Yong Gyu Gwak
Internal Auditor · since 2024
Seok Yeong Gwon
Assistant Managing Director
Gi Jeong Kim
Assistant Managing Director
Gil Sun Kim
Assistant Managing Director
Gi Deok Kim
Assistant Managing Director
Jin Yi Kim
Assistant Managing Director
Mi Seon Kim
Assistant Managing Director
Jun Hui Lee
Assistant Managing Director
Geun Jae Lee
Assistant Managing Director
Min Ho Lee
Assistant Managing Director
Jang Su Moon
Assistant Managing Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||